The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Open accessAbstract
PURPOSE: To determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression–based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405. PATIENTS AND METHODS: CALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients. RESULTS: The CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS ( P for interaction < .001) and PFS ( P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab ( P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab ( P = .0046). CONCLUSION: These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bevacizumab is effective regardless of RAS gene status”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
Mann, H. B., & Whitney, D. R. (1947) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177730491 · Cited by 14,320
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationColorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Cancer treatment and survivorship statistics, 2012
Siegel, R. L., Desantis, C. E., Virgo, K. S., Stein, K., Mariotto, A. B., Smith, T. G., Cooper, D. L., Gansler, T. S., Lerro, C. C., Fedewa, S. A., et al. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,979
Cancer treatment and survivorship statistics, 2014
Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Research works printed but not linked: 1
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Sorted by citations
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Eng, C., Yoshino, T., Ruíz‐García, E., Mostafa, N., Cann, C., O’Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 508
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 272
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
Stintzing, S., Wirapati, P., Lenz, H., Neureiter, D., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al‐Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 196
Self-citationCurrent Achievements and Applications of Transcriptomics in Personalized Cancer Medicine
Supplitt, S., Karpiński, P., Sasiadek, M. M., & Łaczmańska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031422 · Cited by 166
Okita, A., Takahashi, S. I., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24617 · Cited by 162
Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
Kanani, A. N., Veen, T., & Søreide, K. (2021) · British journal of surgery · doi:10.1093/bjs/znab342 · Cited by 135
Single‐cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer
Xia, J., Xie, Z., Niu, G., Lu, Z., Wang, Z., Xing, Y., Ren, J., Hu, Z., Hong, R., Cao, Z., et al. (2022) · Immunology · doi:10.1111/imm.13568 · Cited by 128
Molecular characterization of colorectal cancer related peritoneal metastatic disease
Lenos, K. J., Bach, S., Ferreira Moreno, L., ten Hoorn, S., Sluiter, N. R., Bootsma, S., Vieira Braga, F. A., Nijman, L. E., van den Bosch, T., Miedema, D. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32198-z · Cited by 125
Rumpold, H. F., Niedersüß‐Beke, D., Heiler, C., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07656-w · Cited by 122
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 116
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Bianchi, A. S., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 116
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges
Qian, Y., Daza, J., Itzel, T., Betge, J., Zhan, T., Marmé, F., & Teufel, A. (2021) · Cells · doi:10.3390/cells10030648 · Cited by 112
Traditional Classification and Novel Subtyping Systems for Bladder Cancer
Zhu, S., Yu, W., Yang, X., Wu, C., & Fan, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00102 · Cited by 104
Immune scores in colorectal cancer: Where are we?
Malka, D., Lièvre, A., André, T., Taı̈eb, J., Ducreux, M. P., & Bibeau, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.024 · Cited by 101
Huyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 106
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 102
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 96
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
Eide, P. W., Moosavi, S. H., Eilertsen, I. A., Brunsell, T. H., Langerud, J., Berg, K. C. G., Røsok, B. I., Bjørnbeth, B. A., Nesbakken, A., Lothe, R. A., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00223-7 · Cited by 70
BRAF Mutated Colorectal Cancer: New Treatment Approaches
Molina‐Cerrillo, J., Román, M. S., Pozas, J., Alonso‐Gordoa, T., Pozas, M., Conde, E., Cancio-Suárez, M. R., Grande, E., García‐Bermejo, L., & Carrato, A. (2020) · Cancers · doi:10.3390/cancers12061571 · Cited by 78
γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors
Harmon, C., Zaborowski, A. M., Moore, H., Louis, P. S., Slattery, K., Duquette, D., Scanlan, J., Kane, H., Kunkemoeller, B. H., McIntyre, C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00589-w · Cited by 78
Lenz, H., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Élez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008409 · Cited by 83
Self-citationIntratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0529 · Cited by 68
Advances in colon cancer research: in vitro and animal models
Lannagan, T. R. M., Jackstadt, R., Leedham, S. J., & Sansom, O. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.003 · Cited by 74
Investigation of colorectal cancer in accordance with consensus molecular subtype classification
Sawayama, H., Miyamoto, Y., Ogawa, K., Yoshida, N., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12362 · Cited by 60
Abraham, J. P., Magee, D., Cremolini, C., Antoniotti, C., Halbert, D. D., Xiu, J., Stafford, P., Berry, D. A., Oberley, M. J., Shields, A. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3286 · Cited by 67
Self-citationPrognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization
Zhan, Y., Zheng, L., Liu, J., Hu, D., Wang, J., Liu, K., Guo, J., Zhang, T., & Kong, D. (2021) · JCI Insight · doi:10.1172/jci.insight.148028 · Cited by 53
Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
Valenzuela, G., Canepa, J., Simonetti, C., de Zaldívar, L. S., Marcelain, K., & González‐Montero, J. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i11.1000 · Cited by 52
Phipps, A. I., Alwers, E., Harrison, T. A., Banbury, B. L., Brenner, H., Campbell, P. T., Chang-Claude, J. C., Buchanan, D. D., Chan, A. T., Farris, A. B., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.029 · Cited by 54
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 57
Johnson, D., Chee, C. E., Wong, W., Lam, R. C. T., Tan, I. B. H., & Ma, B. B. Y. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102700 · Cited by 48
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 43
Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis
Wu, X., Yan, H., Qiu, M., Qu, X., Wang, J., Xu, S., Zheng, Y., Ge, M., Yan, L., & Li, L. (2023) · eLife · doi:10.7554/elife.86032 · Cited by 45
Self-citationSnyder, R. A., Hu, C., Zafar, S. N., Francescatti, A. B., & Chang, G. J. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa182 · Cited by 39
HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome
Golkaram, M., Salmans, M., Kaplan, S., Vijayaraghavan, R., Martins, M., Khan, N., Garbutt, C. C., Wise, A. S., Yao, J., Casimiro, S., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00177-w · Cited by 41
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways
Gudiño, V., Pohl, S., Billard, C. V., Cammareri, P., Bolado‐Carrancio, A., Aitken, S., Stevenson, D., Hall, A. E., Agostino, M., Cassidy, J. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22531-3 · Cited by 40
Colloca, G. A., Venturino, A., & Guarneri, D. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02277-7 · Cited by 38
Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2403 · Cited by 36
Colorectal cancer and therapy response: a focus on the main mechanisms involved
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208140 · Cited by 37
Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision
Reberšek, M. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0031 · Cited by 36
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
Moosavi, S. H., Eide, P. W., Eilertsen, I. A., Brunsell, T. H., Berg, K. C. G., Røsok, B. I., Brudvik, K. W., Bjørnbeth, B. A., Guren, M. G., Nesbakken, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00956-1 · Cited by 34
Buechler, S. A., Stephens, M., Hummon, A. B., Ludwig, K. R., Cannon, E. E., Carter, T. C., Resnick, J. M., Gökmen‐Polar, Y., & Badve, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-69083-y · Cited by 34
Li, Y., Yao, Q., Zhang, L., Mo, S., Cai, S., Huang, D., & Peng, J. (2020) · The Oncologist · doi:10.1002/onco.13521 · Cited by 35
Du, T., Gao, Q., Zhao, Y., Gao, J., Li, J., Wang, L., Li, P., Wang, Y., Du, L., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651796 · Cited by 33
Li, Y., Mo, S., Zhang, L., Ma, X., Hu, X., Huang, D., Lu, B., Luo, C., Peng, H., Cai, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.010 · Cited by 32
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 33
Randon, G., Maddalena, G., Germani, M. M., Pircher, C. C., Manca, P., Bergamo, F., Giordano, M., Sposetti, C., Montagna, A., Vetere, G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00037 · Cited by 34
Molecular description of ANGPT2 associated colorectal carcinoma
Jary, M., Hasanova, R., Vienot, A., Asgarov, K., Loyon, R., Tirole, C., Bouard, A., Orillard, É., Klajer, É., Kim, S. C. H., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32993 · Cited by 30
Wilkinson, K. J., Ng, W. L., Roberts, T. L., Becker, T. M., Lim, S. H.-S., Chua, W. M., & Lee, C. S. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207309 · Cited by 31
Puzzo, M., Santo, M. D., Morelli, C., Leggio, A., Catalano, S., & Pasqua, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031313 · Cited by 31
Moretto, R., Corallo, S., Belfiore, A., Rossini, D., Boccaccino, A., Lonardi, S., Centonze, G., Morano, F., Germani, M. M., Loupakis, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.045 · Cited by 29
Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
Chowdhury, S., Hofree, M., Lin, K., Maru, D. M., Kopetz, S., & Shen, J. P. (2021) · Cancers · doi:10.3390/cancers13194923 · Cited by 29
From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer
Banias, L., Jung, I., Chiciudean, R., & Gurzu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169455 · Cited by 30
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Kim, J., Kim, H. J., Lee, M.-S., Lee, H., Kim, Y. J., Lee, W. Y., Yun, S. H., Kim, H. C., Hong, H. K., Hannenhalli, S. S., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04053-2 · Cited by 28
Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 28
Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth
Bernier‐Latmani, J., Cisarovsky, C., Mahfoud, S., Ragusa, S., Dupanloup, I., Barras, D., Renevey, F., Nassiri, S., Anderle, P., Squadrito, M. L., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00061-5 · Cited by 26
Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07316-z · Cited by 27
Ohnmacht, A. J., Stahler, A., Stintzing, S., Modest, D. P., Holch, J. W., Westphalen, C. B., Hölzel, L., Schübel, M. K., Galhoz, A., Farnoud, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41011-4 · Cited by 25
Cancer of Unknown Primary Site
Raghav, K. P. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmcp2402691 · Cited by 25
Qu, R., Zhang, Y., Kim, B., Zeng, G., Wang, P., Shaoyong, W., Huang, Y., Guo, W., Chen, Y., Wang, P., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.002 · Cited by 29
Stahler, A., Stintzing, S., von Einem, J. C., Westphalen, C. B., Heinrich, K., Krämer, N., Michl, M., Modest, D. P., von Weikersthal, L. F., Decker, T. W., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.003 · Cited by 25
Sun, J., Chen, Y., Xu, Z., Wang, W., & Li, P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06282-z · Cited by 24
Tomasini, P. P., Guecheva, T. N., Leguisamo, N. M., Péricart, S., Brunac, A., Hoffmann, J., & Saffi, J. (2021) · Cancers · doi:10.3390/cancers13133130 · Cited by 25
ten Hoorn, S., Sommeijer, D. W., Elliott, F., Fisher, D. J., de Back, T. R., Trinh, A. C., Koens, L., Maughan, T., Seligmann, J. F., Seymour, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01477-9 · Cited by 25
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
Shimozaki, K., Nakayama, I., Hirota, T., & Yamaguchi, K. (2023) · Cells · doi:10.3390/cells12071049 · Cited by 25
Xu, C., Mannucci, A., Esposito, F. M., Oliveres, H., Alonso-Orduña, V., Yubero, A., Fernández-Martos, C., Salud, A., Gallego-Plazas, J., Martín-Richard, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1934 · Cited by 23
Prognostic and predictive molecular biomarkers in colorectal cancer
Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., & Li, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1532924 · Cited by 24
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
Thota, R., Yang, M., Pflieger, L. T., Schell, M. J., Rajan, M., Davis, T. B., Wang, H., Presson, A. P., Pledger, W. J., & Yeatman, T. J. (2021) · Cancers · doi:10.3390/cancers13215394 · Cited by 22
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes
Sveen, A., Cremolini, C., & Dienstmann, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz412 · Cited by 22
Ding, X., Huang, H., Zhang, F., & Jiang, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01282-5 · Cited by 22
Li, X., Larsson, P. G., Ljuslinder, I., Ling, A., Löfgren‐Burström, A., Zingmark, C., Edin, S., & Palmqvist, R. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153379 · Cited by 21
Kryczka, J. M., & Boncela, J. (2022) · Biomedicines · doi:10.3390/biomedicines10071720 · Cited by 21
Chen, Y., Guo, X., Liu, M.-L., Yu, Y., Cui, Y., Shen, X., Liu, T., & Liang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.979521 · Cited by 21
Sherman, S. K., Schuitevoerder, D., Chan, C. H. F., & Turaga, K. K. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08733-x · Cited by 21
Dang, Q., Zuo, L., Hu, X., Zhou, Z., Chen, S., Liu, S., Ba, Y., Zuo, A., Xu, H., Weng, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70041 · Cited by 27
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?
Arrichiello, G., Poliero, L., Borrelli, C., Paragliola, F., Nacca, V., Napolitano, S., Corte, C. M. D., Martini, G., & Martinelli, E. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100442 · Cited by 20
Kozuka, M., Battaglin, F., Jayachandran, P., Wang, J., Arai, H., Soni, S., Zhang, W., Hirai, M., Matsusaka, S., & Lenz, H. (2021) · Cancers · doi:10.3390/cancers13194862 · Cited by 20
Self-citationInnocenti, F., Yazdani, A., Rashid, N., Qu, X., Ou, F., Buren, S. V., Bertagnolli, M. M., Kabbarah, O., Blanke, C. D., Venook, A. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3202 · Cited by 20
Self-citationUlanja, M. B., Ntafam, C., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., Ulanja, R. N., Mabrouk, T., Governor, S., Djankpa, F. T., & Alese, O. B. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27096 · Cited by 23
Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review)
Wang, C., Zhang, H., Liu, Y., Wang, Y., Hu, H., & Wang, G. (2023) · Oncology Letters · doi:10.3892/ol.2023.13816 · Cited by 22
Battaglin, F., Ou, F., Qu, X., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Ashouri, K., Zemla, T., Blanke, C. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01507 · Cited by 21
Self-citationKantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 19
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Yoshikawa, A., & Nakamura, Y. (2022) · Cancers · doi:10.3390/cancers15010183 · Cited by 21
Molecular subtyping improves prognostication of Stage 2 colorectal cancer
Purcell, R. V., Schmeier, S., Lau, Y. C., Pearson, J. F., & Frizelle, F. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-6327-4 · Cited by 19
Chowdhury, S., Xiu, J., Ribeiro, J. R., Nicolaides, T. P., Zhang, J., Korn, W. M., Poorman, K. A., Lenz, H., Marshall, J. L., Oberley, M. J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02826-0 · Cited by 20
Self-citationLenz, H., Argilés, G., Yoshino, T., Tejpar, S., Ciardiello, F., Braunger, J., Salnikov, A. V., Gabrielyan, O., Schmid, R., Höfler, J., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.09.003 · Cited by 18
Self-citationDevelopment of a miRNA‐based classifier for detection of colorectal cancer molecular subtypes
Adam, R., Poel, D., Moreno, L. F., Spronck, J., de Back, T. R., Torang, A., Barila, P. M. G., ten Hoorn, S., Markowetz, F. M., Wang, X., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13210 · Cited by 17
Giordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D'Andrea, M. R., Santis, E. D., Coppola, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147717 · Cited by 19
Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100073 · Cited by 17
Metadata
- Authors
- Lenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., Qu, X., Wirapati, P., Tejpar, S., Innocenti, F., & Kabbarah, O.
- Affiliations
- USC Norris Comprehensive Cancer Center (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Yale Cancer Center, New Haven, CT
- Duke Medical Center (US)
- West Virginia University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Genentech (US)
- SIB Swiss Institute of Bioinformatics (CH)
- Universitair Ziekenhuis Leuven (BE)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-08-01
- Volume
- 37
- Issue
- 22
- Pages
- 1876-1885
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC6675593
- OpenAlex
- W2943196840
- Cited by
- 246
- References
- 35
- Citations by year
- 2026: 11 · 2025: 31 · 2024: 28 · 2023: 27 · 2022: 39 · 2021: 61 · 2020: 37 · 2019: 8
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-02-07)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Pfizer
- Bayer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Baxalta
- Taiho Pharmaceutical
- Exelixis
- Jazz Pharmaceuticals
- Leidos
- BeiGene
- Incyte
- Eisai
- National Institutes of Health (UL1TR001863)
- Genentech
- Takeda Oncology
- Pharmacyclics
- National Cancer Institute (U10CA180882, U10CA180820, U10CA180791, UG1CA233290, U10CA180888, U10CA180836, U10CA180790, UG1CA233331, UG1CA233180, U10CA180830, U10CA180795, U10CA180850, U10CA180838, U10CA180867, U10CA180821, UG1CA180830, U10CA180799)
- National Institute of General Medical Sciences (U54GM104942)
- National Center for Advancing Translational Sciences
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- consensus molecular subtypes, metastatic colorectal cancer, prognostic factors, predictive biomarkers, bevacizumab, cetuximab, first-line chemotherapy, overall survival, progression-free survival, targeted therapy selection
- MeSH terms
- Bevacizumab, Cetuximab, Irinotecan, Oxaliplatin, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Predictive Value of Tests, Prognosis, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease-Free Survival, Gene Expression Profiling, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
